(54) Title: NOVEL COMPOUNDS

(57) Abstract

The invention provides valS polypeptides and DNA (RNA) encoding valS polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing valS polypeptides to screen for antibacterial compounds.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>AL</td>
<td>Albania</td>
<td>ES</td>
<td>Spain</td>
<td>LS</td>
<td>Lesotho</td>
</tr>
<tr>
<td>AM</td>
<td>Armenia</td>
<td>FI</td>
<td>Finland</td>
<td>LT</td>
<td>Lithuania</td>
</tr>
<tr>
<td>AT</td>
<td>Austria</td>
<td>FR</td>
<td>France</td>
<td>LU</td>
<td>Luxembourg</td>
</tr>
<tr>
<td>AU</td>
<td>Australia</td>
<td>GA</td>
<td>Gabon</td>
<td>LV</td>
<td>Latvia</td>
</tr>
<tr>
<td>AZ</td>
<td>Azerbaijan</td>
<td>GB</td>
<td>United Kingdom</td>
<td>MC</td>
<td>Monaco</td>
</tr>
<tr>
<td>BA</td>
<td>Bosnia and Herzegovina</td>
<td>GE</td>
<td>Georgia</td>
<td>MD</td>
<td>Republic of Moldova</td>
</tr>
<tr>
<td>BB</td>
<td>Barbados</td>
<td>GH</td>
<td>Ghana</td>
<td>MG</td>
<td>Madagascar</td>
</tr>
<tr>
<td>BE</td>
<td>Belgium</td>
<td>GN</td>
<td>Guinea</td>
<td>MK</td>
<td>The former Yugoslav</td>
</tr>
<tr>
<td>BF</td>
<td>Burkina Faso</td>
<td>GR</td>
<td>Greece</td>
<td>ML</td>
<td>Republic of Macedonia</td>
</tr>
<tr>
<td>BG</td>
<td>Bulgaria</td>
<td>HU</td>
<td>Hungary</td>
<td>ML</td>
<td>Mali</td>
</tr>
<tr>
<td>BJ</td>
<td>Benin</td>
<td>IE</td>
<td>Ireland</td>
<td>MN</td>
<td>Mongolia</td>
</tr>
<tr>
<td>BR</td>
<td>Brazil</td>
<td>IL</td>
<td>Israel</td>
<td>MR</td>
<td>Mauritania</td>
</tr>
<tr>
<td>BY</td>
<td>Belarus</td>
<td>IS</td>
<td>Iceland</td>
<td>MW</td>
<td>Malawi</td>
</tr>
<tr>
<td>CA</td>
<td>Canada</td>
<td>IT</td>
<td>Italy</td>
<td>MX</td>
<td>Mexico</td>
</tr>
<tr>
<td>CF</td>
<td>Central African Republic</td>
<td>JP</td>
<td>Japan</td>
<td>NE</td>
<td>Niger</td>
</tr>
<tr>
<td>CG</td>
<td>Congo</td>
<td>KE</td>
<td>Kenya</td>
<td>NL</td>
<td>Netherlands</td>
</tr>
<tr>
<td>CH</td>
<td>Switzerland</td>
<td>KG</td>
<td>Kyrgyzstan</td>
<td>NO</td>
<td>Norway</td>
</tr>
<tr>
<td>CI</td>
<td>Côte d'Ivoire</td>
<td>KF</td>
<td>Democratic People's Republic of Korea</td>
<td>NZ</td>
<td>New Zealand</td>
</tr>
<tr>
<td>CM</td>
<td>Cameroon</td>
<td>KR</td>
<td>Republic of Korea</td>
<td>PL</td>
<td>Poland</td>
</tr>
<tr>
<td>CN</td>
<td>China</td>
<td>KZ</td>
<td>Kazakhstan</td>
<td>PT</td>
<td>Portugal</td>
</tr>
<tr>
<td>CU</td>
<td>Cuba</td>
<td>LC</td>
<td>Saint Lucia</td>
<td>RO</td>
<td>Romania</td>
</tr>
<tr>
<td>CZ</td>
<td>Czech Republic</td>
<td>LI</td>
<td>Liechtenstein</td>
<td>RU</td>
<td>Russian Federation</td>
</tr>
<tr>
<td>DE</td>
<td>Germany</td>
<td>LK</td>
<td>Sri Lanka</td>
<td>SD</td>
<td>Sudan</td>
</tr>
<tr>
<td>DK</td>
<td>Denmark</td>
<td>LR</td>
<td>Liberia</td>
<td>SE</td>
<td>Sweden</td>
</tr>
<tr>
<td>EE</td>
<td>Estonia</td>
<td></td>
<td></td>
<td>SG</td>
<td>Singapore</td>
</tr>
<tr>
<td>SI</td>
<td>Slovenia</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SK</td>
<td>Slovakia</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SN</td>
<td>Senegal</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SZ</td>
<td>Swaziland</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TD</td>
<td>Chad</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TG</td>
<td>Togo</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TJ</td>
<td>Tajikistan</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TM</td>
<td>Turkmenistan</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TR</td>
<td>Turkey</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TT</td>
<td>Trinidad and Tobago</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>UA</td>
<td>Ukraine</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>UG</td>
<td>Uganda</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>US</td>
<td>United States of America</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>UZ</td>
<td>Uzbekistan</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VN</td>
<td>Viet Nam</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>YU</td>
<td>Yugoslavia</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ZW</td>
<td>Zimbabwe</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
NOVEL COMPOUNDS

RELATED APPLICATIONS

This application claims priority to UK application number 9607991.8, filed April 18, 1996.

FIELD OF THE INVENTION

This invention relates to newly identified polynucleotides and polypeptides, and their production and uses, as well as their variants, agonists and antagonists, and their uses. In particular, in these and in other regards, the invention relates to novel polynucleotides and polypeptides of the valyl tRNA synthetase family, hereinafter referred to as "valS".

BACKGROUND OF THE INVENTION

The Streptococci make up a medically important genera of microbes known to cause several types of disease in humans, including, for example, otitis media, conjunctivitis, pneumonia, bacteremia, meningitis, sinusitis, pleural empyema and endocarditis, and most particularly meningitis, such as for example infection of cerebrospinal fluid. Since its isolation more than 100 years ago, *Streptococcus pneumoniae* has been one of the more intensively studied microbes. For example, much of our early understanding that DNA is, in fact, the genetic material was predicated on the work of Griffith and of Avery, Macleod and McCarty using this microbe. Despite the vast amount of research with *S. pneumoniae*, many questions concerning the virulence of this microbe remain. It is particularly preferred to employ Streptococal genes and gene products as targets for the development of antibiotics.

The frequency of *Streptococcus pneumoniae* infections has risen dramatically in the past 20 years. This has been attributed to the emergence of multiply antibiotic resistant strains and an increasing population of people with weakened immune systems. It is no longer uncommon to isolate *Streptococcus pneumoniae* strains which are resistant to some or all of the standard antibiotics. This has created a demand for both new anti-microbial agents and diagnostic tests for this organism.

The t-RNA synthetases have a primary role in protein synthesis according to the following scheme:

\[
\text{Enzyme + ATP + AA } \leftrightarrow \text{ Enzyme.AA-AMP + PPI}
\]

\[
\text{Enzyme.AA-AMP + t-RNA } \leftrightarrow \text{ Enzyme + AMP + AA-t-RNA}
\]

in which AA is an amino acid.

Inhibition of this process leads to a reduction in the levels of charged t-RNA and this triggers a cascade of responses known as the stringent response, the result of which is the induction of a state of dormancy in the organism. As such selective inhibitors of bacterial t-
RNA synthetase have potential as antibacterial agents. One example of such is mupirocin which is a selective inhibitor of isoleucyl t-RNA synthetase. Other t-RNA synthetases are now being examined as possible anti-bacterial targets, this process being greatly assisted by the isolation of the synthetase.

Clearly, there is a need for factors, such as the novel compounds of the invention, that have a present benefit of being useful to screen compounds for antibiotic activity. Such factors are also useful to determine their role in pathogenesis of infection, dysfunction and disease. There is also a need for identification and characterization of such factors and their antagonists and agonists which can play a role in preventing, ameliorating or correcting infections, dysfunctions or diseases.

The polypeptides of the invention have amino acid sequence homology to a known *Bacillus stearothermophilus* valyl tRNA synthetase protein.

**SUMMARY OF THE INVENTION**

It is an object of the invention to provide polypeptides that have been identified as novel valS polypeptides by homology between the amino acid sequence set out in Table 1 [SEQ ID NO: 2] and a known amino acid sequence or sequences of other proteins such as *Bacillus stearothermophilus* valyl tRNA synthetase protein.

It is a further object of the invention to provide polynucleotides that encode valS polypeptides, particularly polynucleotides that encode the polypeptide herein designated valS.

In a particularly preferred embodiment of the invention the polynucleotide comprises a region encoding valS polypeptides comprising a sequence set out in Table 1 [SEQ ID NOS:1, 5, 6, 9], or a variant thereof.

In another particularly preferred embodiment of the invention there is a novel valS protein from *Streptococcus pneumoniae* comprising an amino acid sequence of Table 1 [SEQ ID NOS:2, 7, 8, 10], or a variant thereof.

In accordance with another aspect of the invention there is provided an isolated nucleic acid molecule encoding a mature polypeptide expressible by the *Streptococcus pneumoniae* 0100993 strain contained in the deposited strain.

A further aspect of the invention there are provided isolated nucleic acid molecules encoding valS, particularly *Streptococcus pneumoniae* valS, including mRNAs, cDNAs, genomic DNAs. Further embodiments of the invention include biologically, diagnostically, prophylactically, clinically or therapeutically useful variants thereof, and compositions comprising the same.
In accordance with another aspect of the invention, there is provided the use of a polynucleotide of the invention for therapeutic or prophylactic purposes, in particular genetic immunization. Among the particularly preferred embodiments of the invention are naturally occurring allelic variants of valS and polypeptides encoded thereby.

Another aspect of the invention there are provided novel polypeptides of *Streptococcus pneumoniae* referred to herein as valS as well as biologically, diagnostically, prophylactically, clinically or therapeutically useful variants thereof, and compositions comprising the same.

Among the particularly preferred embodiments of the invention are variants of valS polypeptide encoded by naturally occurring alleles of the valS gene.

In a preferred embodiment of the invention there are provided methods for producing the aforementioned valS polypeptides.

In accordance with yet another aspect of the invention, there are provided inhibitors to such polypeptides, useful as antibacterial agents, including, for example, antibodies.

In accordance with certain preferred embodiments of the invention, there are provided products, compositions and methods for assessing valS expression, treating disease, for example, otitis media, conjunctivitis, pneumonia, bacteremia, meningitis, sinusitis, pleural empyema and endocarditis, and most particularly meningitis, such as for example infection of cerebrospinal fluid, assaying genetic variation, and administering a valS polypeptide or polynucleotide to an organism to raise an immunological response against a bacteria, especially a *Streptococcus pneumoniae* bacteria.

In accordance with certain preferred embodiments of this and other aspects of the invention there are provided polynucleotides that hybridize to valS polynucleotide sequences, particularly under stringent conditions.

In certain preferred embodiments of the invention there are provided antibodies against valS polypeptides.

In other embodiments of the invention there are provided methods for identifying compounds which bind to or otherwise interact with and inhibit or activate an activity of a polypeptide or polynucleotide of the invention comprising: contacting a polypeptide or polynucleotide of the invention with a compound to be screened under conditions to permit binding to or other interaction between the compound and the polypeptide or polynucleotide to assess the binding to or other interaction with the compound, such binding or interaction being associated with a second component capable of providing a detectable signal in response to the binding or interaction of the polypeptide or polynucleotide with the compound; and determining whether the compound binds to or otherwise interacts with and activates or inhibits an activity of
the polypeptide or polynucleotide by detecting the presence or absence of a signal generated from
the binding or interaction of the compound with the polypeptide or polynucleotide.

In accordance with yet another aspect of the invention, there are provided valS agonists
and antagonists, preferably bacteriostatic or bacteriocidal agonists and antagonists.

In a further aspect of the invention there are provided compositions comprising a valS
polynucleotide or a valS polypeptide for administration to a cell or to a multicellular organism.

Various changes and modifications within the spirit and scope of the disclosed invention
will become readily apparent to those skilled in the art from reading the following descriptions
and from reading the other parts of the present disclosure.

GLOSSARY

The following definitions are provided to facilitate understanding of certain terms used
frequently herein.

"Host cell" is a cell which has been transformed or transfected, or is capable of
transformation or transfection by an exogenous polynucleotide sequence.

"Identity," as known in the art, is a relationship between two or more polypeptide
sequences or two or more polynucleotide sequences, as determined by comparing the sequences.
In the art, "identity" also means the degree of sequence relatedness between polypeptide or
polynucleotide sequences, as the case may be, as determined by the match between strings
of such sequences. "Identity" and "similarity" can be readily calculated by known methods,
including but not limited to those described in (Computational Molecular Biology, Lesk,
A.M., ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and
of Sequence Data, Part I, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey,
1994; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; and
Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New
Preferred methods to determine identity are designed to give the largest match between the
sequences tested. Methods to determine identity and similarity are codified in publicly
available computer programs. Preferred computer program methods to determine identity
and similarity between two sequences include, but are not limited to, the GCG program
package (Devereux, J., et al., Nucleic Acids Research 12(1): 387 (1984)), BLASTP,
BLAST X program is publicly available from NCBI and other sources (BLAST Manual,
215: 403-410 (1990). As an illustration, by a polynucleotide having a nucleotide sequence having at least, for example, 95% "identity" to a reference nucleotide sequence of SEQ ID NO: 1 it is intended that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence of SEQ ID NO: 1. In other words, to obtain a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. These mutations of the reference sequence may occur at the 5 or 3 terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence. Analogously, by a polypeptide having an amino acid sequence having at least, for example, 95% identity to a reference amino acid sequence of SEQ ID NO: 2 is intended that the amino acid sequence of the polypeptide is identical to the reference sequence except that the polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the reference amino acid of SEQ ID NO: 2. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a reference amino acid sequence, up to 5% of the amino acid residues in the reference sequence may be deleted or substituted with another amino acid, or a number of amino acids up to 5% of the total amino acid residues in the reference sequence may be inserted into the reference sequence. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

"Isolated" means altered "by the hand of man" from its natural state, i.e., if it occurs in nature, it has been changed or removed from its original environment, or both. For example, a polynucleotide or a polypeptide naturally present in a living organism is not "isolated," but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is "isolated", as the term is employed herein.

"Polynucleotide(s)" generally refers to any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. "Polynucleotide(s)" include, without limitation, single- and double-stranded DNA, DNA that is a
mixture of single- and double-stranded regions or single-, double- and triple-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded, or triple-stranded regions, or a mixture of single- and double-stranded regions. In addition, "polynucleotide" as used herein refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The strands in such regions may be from the same molecule or from different molecules. The regions may include all of one or more of the molecules, but more typically involve only a region of some of the molecules. One of the molecules of a triple-helical region often is an oligonucleotide. As used herein, the term "polynucleotide(s)" also includes DNAs or RNAs as described above that contain one or more modified bases. Thus, DNAs or RNAs with backbones modified for stability or for other reasons are "polynucleotide(s)" as that term is intended herein. Moreover, DNAs or RNAs comprising unusual bases, such as inosine, or modified bases, such as tritylated bases, to name just two examples, are polynucleotides as the term is used herein. It will be appreciated that a great variety of modifications have been made to DNA and RNA that serve many useful purposes known to those of skill in the art. The term "polynucleotide(s)" as it is employed herein embraces such chemically, enzymatically or metabolically modified forms of polynucleotides, as well as the chemical forms of DNA and RNA characteristic of viruses and cells, including, for example, simple and complex cells. "Polynucleotide(s)" also embraces short polynucleotides often referred to as oligonucleotide(s).

"Polypeptide(s)" refers to any peptide or protein comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds. "Polypeptide(s)" refers to both short chains, commonly referred to as peptides, oligopeptides and oligomers and to longer chains generally referred to as proteins. Polypeptides may contain amino acids other than the 20 gene encoded amino acids. "Polypeptide(s)" include those modified either by natural processes, such as processing and other post-translational modifications, but also by chemical modification techniques. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature, and they are well known to those of skill in the art. It will be appreciated that the same type of modification may be present in the same or varying degree at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains, and the amino or carboxyl termini. Modifications include, for example, acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a

"Variant(s)" as the term is used herein, is a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide respectively, but retains essential properties. A typical variant of a polynucleotide differs in nucleotide sequence from another, reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below. A typical variant of a polypeptide differs in amino acid sequence from another, reference polypeptide. Generally, differences are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical. A variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, additions, deletions in any combination. A substituted or inserted amino acid residue may or may not be one encoded by the genetic code. A variant of a polynucleotide or polypeptide may be a naturally occurring such as an allelic variant, or it may be a variant that is not known to occur naturally. Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques, by direct synthesis, and by other recombinant methods known to skilled artisans.
DESCRIPTION OF THE INVENTION

The invention relates to novel valS polypeptides and polynucleotides as described in
greater detail below. In particular, the invention relates to polypeptides and polynucleotides of a
novel valS of *Streptococcus pneumoniae*, which is related by amino acid sequence homology to
*Bacillus stearothermophilus* valyl tRNA synthetase polypeptide. The invention relates
especially to valS comprising the nucleotide and amino acid sequences set out in Table 1 [SEQ
ID NO: 1, 5, 6, 9] and Table 1 [SEQ ID NO: 2, 7, 8, 10] respectively, and to the valS nucleotide
sequences of the DNA in the deposited strain and amino acid sequences encoded thereby.

---

TABLE 1

valS Polynucleotide and Polypeptide Sequences

(A) Sequences from *Streptococcus pneumoniae* valS polynucleotide sequence.

Fragment 1 [SEQ ID NO: 1]

| Position | Sequence
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>5'→1</td>
<td>ATGTCTAAAG AACTTTTAC TAAATACAAT CCAGCGAGG TTGAGGCTGG</td>
</tr>
<tr>
<td></td>
<td>TCGTTACCAA AAATGGCTTG ATGCTGATGT TTTCAAGCCT TCAGGCGATC</td>
</tr>
<tr>
<td></td>
<td>AAAAGGCTAA GCCTTATTCA ATCGTTATTC CACCACAAA GTTACAGGT</td>
</tr>
<tr>
<td></td>
<td>AAACCTTACC TTGGTCACGC TTGGGATACA ACTTTGCAAG ATATTATCAT</td>
</tr>
<tr>
<td></td>
<td>CCCTCAAAAA CGCATGCAAG GTTTTGATAC CCTTTGGCTT CTTGGGATGG</td>
</tr>
<tr>
<td>20</td>
<td>ACCACGCAGG GATGCGACT CAGGCTAAAG TAGAGGAGCG CTTGGGCTGT</td>
</tr>
<tr>
<td></td>
<td>GAGGGCATTT CCCGCTATGA CTTTGGTCGT GAGTCTTCTG TGGCAGAAGT</td>
</tr>
<tr>
<td></td>
<td>CTGGAAATGG AAAGCACGAT ATGCCACTAC TATCAAGGAA CAATGGGGCA</td>
</tr>
<tr>
<td>30</td>
<td>AGATGGGGCT CTCTGTAGAC TATTTCTGAT ACGTTTTAC TCTTGACGAA</td>
</tr>
<tr>
<td></td>
<td>GTTTTGCTCA AAGCTTGTCG TAAAGTTTTG GTGGACCTTT ACAAGAAAGG</td>
</tr>
<tr>
<td>35</td>
<td>CTGGATCTAC CGTGGTGAGT TTATCATCAA CTGGGACCCA-3'</td>
</tr>
</tbody>
</table>
5'-1 ATGCTGGAAG ATGGTTCACG CGTCCCTTGAA GTPGCTACAA CTGCTCCTGA

51 GACCATGTTT GGGACGGTG CGGTTGCCGGT CAACCAGAA GACCCGGCGCT

101 ACAAGGACTT GATTTGATTAA AATGTCACTCC TTTCAAATGGC TAATAAACTC

151 ATCCCAATCG TTGGAGATGA GCAAGCAGAT CCGAGGTTTG GTACTGCTGTT

201 CGTGAATAAC ACACCTGCCG ACGATCCAAA TGACCTCTTG GTGGGCCAAC

251 GCTATAAATTT GCCACAAGTG AACGTCATGA ACGACGACGG AACCATAAAT

301 GACTTGCCCT TTGAAATTTC AGGCATGGAC CGTGGGGAAAG CTGCTAAGGC

351 AGTCGTTGCT AAGTTGGGAA AAATCGGTTGC CCTCGTCAA AATCGAAAAAC

401 GTGTGCCAAC GTGTGTCGCA TCAGAGCGTA CAGTGTTTGT GGTGGAACCT

451 CGCTTGCTTA CTCAAGTGTT CGTCAAGATG GACAAATGG CTAAGAAGGC

501 CATTGCCAAC CAAGAACAGC AGGACAAGGT CGAATTCTAC CCACCTCGTT

551 TCAACGATAC CTTCCTTCGA TGGATGGAAA AGTGCACAGA GTGGTTATAC

601 TCTCGTCAGC TCTGTTGGGC TCACCAAAATC CCTGCTGTTG ACAATGCTGA

651 TGTTGAAAATG TATTCGGCCG AAGAAGCGTC AGRAGGTGAC GGATGGACTC

701 AGGACGAAGA CGTCTGTTGA ACTTGTTGTT GAATTGCCCT CTGGCCATT

751 TCAACCATTG GCCTGGCTTG AAGTGACTCA GAAGACTTTA AAGTTATTT

801 CCCAATTCCA ACCTGTTGAA CAGGTTACGA CATCATACCC TTTCTGTGT

851 CTCGTATGAT CTTCAGTCGA TTGGAATTCA CAGGCGTCA ACCATTCAG

901 AACGTCTTCA TCCACGGTCT CATCTGACTG GACCAAGAC GCAAGATCGT

951 TAAGTCTTCG GGTTACCGTA TGAGCCCAAT GGATGTATAC GAGAAATACG

1001 GTGCCGATGG CATTGGTTG GGCATTTCAA ACGGTTCTGC GCCAGGACAA
1051 GACGTGCGTT TCTCTTATGA GAAAAATGAT GCTTCATGGA ACTTTATTAA
1101 CAAGATTGAG AACATTTCCT GCTATATCCT CATGAACAAAT GGAGGTCTGA
5
1151 CGCTGGATGT GCAGCATGAC AATGTCACAA AAGTTGCAAC AGCTGAGGCT
1201 GTTAATGTGA CGGACCCTCTG GATTCTCCAC AATCCTCAACG AAACCATTGC
10
1251 AAAAGTTACT GAAAACCTTT-3'

Fragment 3 [SEQ ID NO:6]

5'-1 ATCAAACGCT TTACAAATCC AGAACACTTG GAAATCGCAT CAACCATCCC
15
51 TGCACCTGAA CTGGATATGT CAACGGTAT TACAGGAGCC GAAATTTCTTCT
101 TGCCACTGGT AGACCTCTTG AATGTCAAGG AAGAATTGGC AGCTCTGGAA
20
151 AAAGAAGTGG CCAAATGGCA GAAAGAACTC GACATGGTGTG CAAAAAACT
201 CAGCAACGGA CCCTCGTGGC CCAACGGTAA ACCAGAACTT GTCCAAAAAG
25
251 AAAAGACAAA ACAAGGCGGAC TACCAAGCGA AGTATGATGT CACCGTGGAC
301 CGTATTGATAG AGATGAAGAA GGTGGTAAAA TAA-3'

(B) valS polypeptide sequence deduced from the polynucleotide sequence in this table.

Encoded by Fragment 1 [SEQ ID NO:2]

30
NH₃-1 MSKELSSKYN PAVEVEAGRYQ KWLDADVFKP SGDQKAKPYS IVIPPNVTVG
51 KLHLGHAWDT TLQDIIRQK RMQGFDTLWL PGMDHAGIAT QAKVEERLRG
35
101 EGISRVDLGR ESFLTVWVEW KDYATTIKE QWGMGLSVD YSRESRFTLDE
151 GLSKAVRKFV VDLYKKGWYI RGEPIINWDP-COOH

Encoded by Fragment 2 [SEQ ID NO:7]

40
NH₃-1 MLEDGSRVLE VATTPPETMF GDVAVAVNPD PPHYKDLICK NVILPIANKL

10
51  IPIVGDEHAD PEFGTVVVI TPAHDNDPL YGQHRHNLPQV NVNMDGGTMN
101 DLAFEFSGMD RFEARKAVVA KLEEGALVK IEKRVHSGH SERTGTVVEP
5
151 RLSTQWFWVK DQLAKNAIAN QDTEDEKVEY PPRFNDTFLQ WMENVHWDVI
201 SRLQAWQHGI PAVY WANGDM YVGEAAEPCG GWTQEDVIDL TWFWSSALWPF
251 STMGWPEVDS EDFKRYFPT S TLVTQYDIIF FWVSRMIFQS LEPTGQRPFO
301 NVLIHGLIRD EQGRKMSKSL GNGIDPMQVI EKYGADALRW FLNSGASPQQ
351 DVRFSYERMD ASWNFINKIW NISRYILMN N GGLTDVAAHD NVTVKATGEA
401 GVTVDRWILH NLNETIAKVT ENF-COOH

Encoded by Fragment 3 [SEQ ID NO:8]

NH₁⁻¹ IKRTINDPEHL EIASTIPAPE LAMSSVITGA EIFLPLVDDL NVEEELARLE
20
51 KELAKWQKEL DMVGGKLSNE RFVANAKPEV YQKEKDKQAD YQAKYDVNTVA
101 RIDEMKOKKVK-COOH

25 (C) Polynucleotide sequence embodiments.

Fragment 1 [SEQ ID NO:1]

X⁻({R₁})ₕ⁻¹ ATGTCTAAAG AACTTTPATC TAAATAACAT CCAAGCCAGG TTGAGGCTGG
30
51 TCCTCATAAC AATGGCTTGT ATGCTGATGT TTTCAAGCCT TCAGGGGATC
101 AAAAGCTAA GCTTATATCA ATCAGTTATTC CACCACCAAA CGTTACAGGT
151 AAACCTCACC TTGTTCACGC TTGGGATACA ACCTTTGCAAG ATATTATCAT
35
201 CCGTCAAAAC CGCATGCAAG GTTTTGATAC CCTTTGGACT TCTGGGATGG
251 ACCACCGAG TATGGCCACT CAGGCTAAGG TAGAGGACGC CTTGCCGTGTT
301 GAGGGGCATT CCGCTATAGA CTTTGGCTGT GAGTCTTTCT TGACGAAAGT
40
351 CTTGGGAGATGG AAAGACGAAT ATGCCACTAC TATCAAGGAA CAATGGGGCA
11
AGATGGGGCT CTCTGTAGAC TATTTCTGTG AGCGTTTCAC TCTTGACGAA
GGTTTTGCAA AAGCTGTTCG TAAGGTCTTT GTGGACCTTT ACAAGAAAAG
CTGGATCTAC CTTTGTGTAGT TTATCATCAA CTGGGACCAC(A_R_2)_n-Y
GACCATGTCT GGGGACGTTC CGGTGTGGGT CAACCCAGAA GACCCGCGCT
ACAAAGGACTT GATTGGAAAA AATGTCATCC TTCAATGGCC TAATAAACTC
ATCCCAATCG TTGGGAGATGA GCCAGCAGAT CCTGAGTTTG GTACTGCTGT
CGTGAAAATG ACACCTGCCA AACGATCCAA TGACTCTTTG GTTGGGCCAA
GCTACATTCT GCCACAAGTC AAGTACTGTA AGCACGACGG AACCATGGAAT
GACTTTGGCC TTGAATTTTC AGGCATGGAC CGTTTTGAAG TCCTGTAGGC
AGTCGTTGCT AAGTTTGAAG AAATCGGTTG CCTCGTCAA AATCGAAAAC
GTGTTCCACAG TGTTGGTCAC TCAGAGCGTA CAGGTGTTGT GTTGGAAACCT
CGCTGTCTCA CTCAATGTTT GTCAAGATG GACCAATGGCG TAAGAAACGC
CATGGCCAAC CAAGACACAG AGGACACGTT CCAATCTTAC CCACCTCGTT
TCAACGATAC CTTCCTTCAA TGGATGGAAA ATGTCCACGA CTGGGTTATC
TCTCGTCAGC TCTGGTGGGG TCACCAAATC CCTGCGCTGT ACAATGCTGA
TGGTGAAATG TATGTCGGCG AAGAAGCTCC AAGAGGTCGA GGTGGACTC
AGGACGAAGA CTCTTGGGTA ACTTTGTTCAA GTTCTGGCCT CTGGCCATT
TCAACCATGG GCTGGGCTGA AGTCGACTCA GAAGACTTTA AAGTTTATT
CCAACTTTCA ACCTTGGTAA CAGGTTACGA CATCATCTTC TTCTGGGGTG
CTCGTATGAT CTTCAGTCA TTGGAATTCA CAGGCCGTCG ACCATTCCAA
AACGTCCTTA TCCACGGTCT CATTCTGACAC GAGCAAGGAC GCAAGATGTC
TAAGTCTTCTG GSTAACCGGGA TTGACCCATA GGATGTATAC GAGAATAACG
GTGCCAGATGC CTTCTGATGG TCTCTTTCGA ACGGCCCTGC GCCAGGACAA
GACGTTGCGT TCTCTTATGA GAAAAATGGAT GCTTCATGGA ACTTTATTAA
CAAGATTTGG AACATTTTCG GCATAATGCT CATGAAACAT GAGGTTTGGGA
CGCTGAGATG GGGCGATGAC AATGTCAACAA AAGTGAGAAG AGGTGAGGCT
GGATAATGGA CGGACCGCTG GATTCCTCAC AATCTCAACG AAACCATTGC
AAAAGTTACT GAAAAACTTT-(R₂)n⁻Y

Fragment 3 [SEQ ID NO:6]

X-(R₁)ₙ⁻¹ ATCAAACGCT TTACAATACC AGAACAATTG GAAATCCGAT CAACCCTGCC
TGCACCTGAA CTGGCTATGT CAAGCGTTAT TACAGGAGCC GAATACTTCT
TGCCACTGTT AGACCTCTTG AATGTCGAAG AAGAATGGCC AGTCTGGAAC
AAAGAACTTG CCAAATGCGA GAAAGAACTC GACATGGTTG GCAAAAAACT
CAAGCAACGAA CCACTCCCTGC CCAACGCTAA ACCAGAGGTT GTCCAAAAAG
AAAAGACCAA ACAAGCCGAC TACCAAGCCA AGTATGATGT GACCGTGAC
CGTATTGATG AGATGAAGAA GTTGTGGAAA TAA-(R₂)ₙ⁻Y

(D) Polypeptide sequence embodiments.

Fragment 1 [SEQ ID NO:2]

X-(R₁)ₙ⁻¹ MSKELSSKYN PAEVEAGRYQ KWLDADVFKP SGDQKAKPS IVIPPPNVTG
KLHLGHAWDT TLQDIIRQK RNQGFDTLWL PGMHAGIAT QAKVEERLRG
EGISRYDGR ESFLTKWVEW KDEYATTIKE QWGMGLSVD YSRERFTLDE
151 GLSKAVRKVF VDLYKKGWYR GREFINWDP-(R<sub>2</sub>)<sub>n</sub>-Y

Fragment 2 [SEQ ID:7]

5  X-(R<sub>1</sub>)<sub>n=1</sub> MLEDGSRLVLE VATTRPETMF GDVAVAVNPE DPRYKDLIGK NVILPIANKL

51  IPIVGDEHAD PEFGTGVVKI TPAHDNPFL VGQRHNLQPQV NVMNDGTMN

10  DLAFESGMD RFEARKAVVA KLEEIGALVK IEKRVHSVGH SERTGVVVEP

101  RLSTQWVFVKM DQLAKNAIAN QDTEDKVEFY PPRFNDTYLQ WMEENVHDWVI

201  SRLWQGHQI PAWYNADGEM YVGEEAPEGD GWTDGEDVLD TWFSSALWPF

251  STMGWPEVDS EDFKRYFPFTS TLVTGDIIF FWSYRMIFQS LEFTGQPPQ

301  NVLHGLIRD EQGRKMSKSL GNGIDPMVDI EKYGADALRW FLSNGSAPQG

351  DVRFSYEKMD ASWNFIKIKW NISRYIMNNN GGLTLDVAHD NVTKVATGEO

401  GNVTDRWILH NLNETIAYKT ENF-(R<sub>2</sub>)<sub>n</sub>-Y

Fragment 3 [SEQ ID:8]

X-(R<sub>1</sub>)<sub>n=1</sub> IKRPTNPEHLE EIATSTPAPE LAMSSVTGAA EIIFLPLVDLL NVVEELARLE

25  KELAKWQKEI DMVGKLSNE RFVANAKPEV VQKEKDQAD YQAKYDVTVA

101  RIDEMKKLV-(R<sub>2</sub>)<sub>n</sub>-Y

30  (E) Polynucleotide sequence embodiment [SEQ ID NO:9]

5'-1  CTGTATTTTC AAGCTTCCAGG CGATCAAAAG GCTAAGCCTT ATTCAATGGT

51  TATTCCACCA CCAACCCTTTA CAGGTAACCT TCACCTTTGG CAGGCTTGGG

35  ATACAACTTTG CAGAGATATT ATCATCCGTC AAAAACACAT GCAGAGTTT

101  GATACCCCTTT GGGCTCTCTGG GATGGACCAC GCAGGGATG CCACCTAGGC

151  GATACCCCTTT GGGCTCTCTGG GATGGACCAC GCAGGGATG CCACCTAGGC

201  TAAGGTAGAG GAGCGCTTGG GTGTTGAGGG CATTCCCCGC TATGACCTTG

251  GTCGTAGAGC TTTCTTGGACG AAAGCTGGG AATGGAAAGA CGAATATGCC
301 ACTACTATCA AGGAACAAATG GGGCAAGATG GGGCTCTCTG TAGACTATTC
351 TCGTGAGCGT TTCACTCTTG ACGAAGGTTT GTCAAAGCCT GTTCTGTAAGG
401 TCTTGTGGA CCTTACAAG AAAGGCTGGA TCTACCCGGG TGAGTTTATC
451 ATCAACTGGG ACCCAGCAG-3'

(F) Polypeptide sequence embodiment [SEQ ID NO:10]

NH₂-1 LMFQASGDQK AKPYSMVIPP PNVTGKLHLLG HAWDITLQDI IIROKRMQGF
51 DTLWLPAGMD AGIATQAKVE ERLRGEGISR YDLGRESFLT KVWEWKDEYA
101 TTIKEQMGKM GLSVDYSRER FTLDEGLSKA VRKVFPVDLYK KGWIYRGEFI
151 INWDA-P-COOH

______________________________
Deposited materials

A deposit containing a *Streptococcus pneumoniae* 0100993 strain has been deposited with the National Collections of Industrial and Marine Bacteria Ltd. (herein "NCIMB"), 23 St. Machar Drive, Aberdeen AB2 1RY, Scotland on 11 April 1996 and assigned deposit number 40794. The deposit was described as *Streptococcus pneumoniae* 0100993 on deposit.

On 17 April 1996 a *Streptococcus pneumoniae* 0100993 DNA library in E. coli was similarly deposited with the NCIMB and assigned deposit number 40800. The *Streptococcus pneumoniae* strain deposit is referred to herein as "the deposited strain" or as "the DNA of the deposited strain."

The deposited strain contains the full length valS gene. The sequence of the polynucleotides contained in the deposited strain, as well as the amino acid sequence of the polypeptide encoded thereby, are controlling in the event of any conflict with any description of sequences herein.

The deposit of the deposited strain has been made under the terms of the Budapest Treaty on the International Recognition of the Deposit of Micro-organisms for Purposes of Patent Procedure. The strain will be irrevocably and without restriction or condition released to the public upon the issuance of a patent. The deposited strain is provided merely as convenience.
to those of skill in the art and is not an admission that a deposit is required for enablement, such as that required under 35 U.S.C. §112.

A license may be required to make, use or sell the deposited strain, and compounds derived therefrom, and no such license is hereby granted.

Polypeptides

The polypeptides of the invention include each polypeptide of Table 1 [SEQ ID NOS:2, 7, 8, 10] (in particular the mature polypeptide) as well as polypeptides and fragments, particularly those which have the biological activity of valS, and also those which have at least 70% identity to a polypeptide of Table 1 [SEQ ID NOS:2, 7, 8, 10] or the relevant portion, preferably at least 80% identity to a polypeptide of Table 1 [SEQ ID NOS:2, 7, 8, 10], and more preferably at least 90% similarity (more preferably at least 90% identity) to a polypeptide of Table 1 [SEQ ID NOS:2, 7, 8, 10] and still more preferably at least 95% similarity (still more preferably at least 95% identity) to a polypeptide of Table 1 [SEQ ID NOS:2, 7, 8, 10] and also include portions of such polypeptides with such portion of the polypeptide generally containing at least 30 amino acids and more preferably at least 50 amino acids.

The invention also includes polypeptides of the formula set forth in Table 1 (D) wherein, at the amino terminus, X is hydrogen, and at the carboxyl terminus, Y is hydrogen or a metal, R₁ and R₂ is any amino acid residue, and n is an integer between 1 and 1000. Any stretch of amino acid residues denoted by either R group, where R is greater than 1, may be either a heteropolymer or a homopolymer, preferably a heteropolymer.

A fragment is a variant polypeptide having an amino acid sequence that entirely is the same as part but not all of the amino acid sequence of the aforementioned polypeptides. As with valS polypeptides fragments may be "free-standing," or comprised within a larger polypeptide of which they form a part or region, most preferably as a single continuous region, a single larger polypeptide.

Preferred fragments include, for example, truncation polypeptides having a portion of an amino acid sequence of Table 1 [SEQ ID NOS:2, 7, 8, 10], or of variants thereof, such as a continuous series of residues that includes the amino terminus, or a continuous series of residues that includes the carboxyl terminus. Degradation forms of the polypeptides of the invention in a host cell, particularly a Streplococcus pneumoniae, are also preferred. Further preferred are fragments characterized by structural or functional attributes such as fragments that comprise alpha-helix and alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions,
alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions.

Also preferred are biologically active fragments which are those fragments that mediate activities of valS, including those with a similar activity or an improved activity, or with a decreased undesirable activity. Also included are those fragments that are antigenic or immunogenic in an animal, especially in a human. Particularly preferred are fragments comprising receptors or domains of enzymes that confer a function essential for viability of *Streptococcus pneumoniae* or the ability to initiate, or maintain cause disease in an individual, particularly a human.

Variants that are fragments of the polypeptides of the invention may be employed for producing the corresponding full-length polypeptide by peptide synthesis; therefore, these variants may be employed as intermediates for producing the full-length polypeptides of the invention.

**Polynucleotides**

Another aspect of the invention relates to isolated polynucleotides that encode the valS polypeptide having a deduced amino acid sequence of Table 1 [SEQ ID NOS:2, 7, 8, 10] and polynucleotides closely related thereto and variants thereof.

Using the information provided herein, such as a polynucleotide sequence set out in Table 1 [SEQ ID NOS:1, 5, 6, 9], a polynucleotide of the invention encoding valS polypeptide may be obtained using standard cloning and screening methods, such as those for cloning and sequencing chromosomal DNA fragments from bacteria using *Streptococcus pneumoniae* 0100993 cells as starting material, followed by obtaining a full length clone. For example, to obtain a polynucleotide sequence of the invention, such as a sequence given in Table 1 [SEQ ID NOS:1, 5, 6, 9], typically a library of clones of chromosomal DNA of *Streptococcus pneumoniae* 0100993 in *E.coli* or some other suitable host is probed with a radiolabeled oligonucleotide, preferably a 17-mer or longer, derived from a partial sequence. Clones carrying DNA identical to that of the probe can then be distinguished using stringent conditions. By sequencing the individual clones thus identified with sequencing primers designed from the original sequence it is then possible to extend the sequence in both directions to determine the full gene sequence. Conveniently, such sequencing is performed using denatured double stranded DNA prepared from a plasmid clone. Suitable techniques are described by Maniatis, T., Fritsch, E.F. and Sambrook et al., *MOLECULAR CLONING, A LABORATORY MANUAL*, 2nd Ed.; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1989). (see in particular Screening By
Hybridization 1.90 and Sequencing Denatured Double-Stranded DNA Templates 13.70).
Illustrative of the invention, a polynucleotide set out in Table 1 [SEQ ID NOS:1, 5, 6, 9] was
discovered in a DNA library derived from Streptococcus pneumoniae 0100993.

The DNA sequence set out in Table 1 [SEQ ID NO:1] contains an open reading frame
5 encoding a protein having about the number of amino acid residues of a polypeptide set forth in
Table 1 [SEQ ID NOS:2, 7, 8, 10] with a deduced molecular weight that can be calculated using
amino acid residue molecular weight values well known in the art. The start codon of the DNA
in Table 1 is nucleotide number 1 (of Fragment 1) and last codon that encodes an amino acid is
number 330 (of Fragment 3), the stop codon being the next codon following this last codon
encoding an amino acid.

valS of the invention is structurally related to other proteins of the valyl tRNA synthetase
family, as shown by the results of sequencing the DNA encoding valS of the deposited strain.
The protein exhibits greatest homology to Bacillus stearothermophilus valyl tRNA synthetase
protein among known proteins. The valS polypeptide of Table 1 [SEQ ID NOS:2, 7, 8, 10] has
about, depending on the fragment, 49-70% identity over its entire length and about 60-81%
similarity over its entire length with the amino acid sequence of Bacillus stearothermophilus
valyl tRNA synthetase polypeptide.

The invention provides a polynucleotide sequence identical over its entire length to each
coding sequence in Table 1 [SEQ ID NOS:1, 5, 6, 9]. Also provided by the invention is the
coding sequence for the mature polypeptide or a fragment thereof, by itself as well as the coding
sequence for the mature polypeptide or a fragment in reading frame with other coding sequence,
such as those encoding a leader or secretory sequence, a pre- or pro- or prepro-protein sequence.
The polynucleotide may also contain non-coding sequences, including for example, but not
limited to non-coding 5' and 3' sequences, such as the transcribed, non-translated sequences,
termination signals, ribosome binding sites, sequences that stabilize mRNA, introns,
polyadenylation signals, and additional coding sequence which encode additional amino acids.
For example, a marker sequence that facilitates purification of the fused polypeptide can be
encoded. In certain embodiments of the invention, the marker sequence is a hexa-histidine
peptide, as provided in the pQE vector (Qiagen, Inc.) and described in Gentz et al., Proc. Natl.
Polynucleotides of the invention also include, but are not limited to, polynucleotides comprising
a structural gene and its naturally associated sequences that control gene expression.
A preferred embodiment of the invention is the polynucleotide comprising nucleotide 1 (Fragment 1) to 330 (Fragment 3) set forth in SEQ ID NO:1 of Table 1 which encodes the valS polypeptide.

The invention also includes polynucleotides of the formula set forth in Table 1 (C) wherein, at the 5' end of the molecule, X is hydrogen, and at the 3' end of the molecule, Y is hydrogen or a metal, R_1 and R_2 is any nucleic acid residue, and n is an integer between 1 and 1000. Any stretch of nucleic acid residues denoted by either R group, where R is greater than 1, may be either a heteropolymer or a homopolymer, preferably a heteropolymer.

The term "polynucleotide encoding a polypeptide" as used herein encompasses polynucleotides that include a sequence encoding a polypeptide of the invention, particularly a bacterial polypeptide and more particularly a polypeptide of the Streptococcus pneumoniae valS comprising an amino acid sequence set out in Table 1 [SEQ ID NOS:2, 7, 8, 10]. The term also encompasses polynucleotides that include a single continuous region or discontinuous regions encoding the polypeptide (for example, interrupted by integrated phage or an insertion sequence or editing) together with additional regions, that also may contain coding and/or non-coding sequences.

The invention further relates to variants of the polynucleotides described herein that encode for variants of the polypeptide comprising a deduced amino acid sequence of Table 1 [SEQ ID NOS:2, 7, 8, 10]. Variants that are fragments of the polynucleotides of the invention may be used to synthesize full-length polynucleotides of the invention.

Further particularly preferred embodiments are polynucleotides encoding valS variants, that have at least one of the amino acid sequence of valS polypeptide of Table 1 [SEQ ID NOS:2, 7, 8, 10] in which several, a few, 5 to 10, 1 to 5, 1 to 3, 2, 1 or no amino acid residues are substituted, deleted or added, in any combination. Especially preferred among these are silent substitutions, additions and deletions, that do not alter the properties and activities of valS.

Further preferred embodiments of the invention are polynucleotides that are at least 70% identical over their entire length to a polynucleotide encoding valS polypeptide having an amino acid sequence set out in Table 1 [SEQ ID NOS:2, 7, 8, 10], and polynucleotides that are complementary to such polynucleotides. Alternatively, most highly preferred are polynucleotides that comprise a region that is at least 80% identical over its entire length to a polynucleotide encoding valS polypeptide of the deposited strain and polynucleotides complementary thereto. In this regard, polynucleotides at least 90% identical over their entire length to the same are particularly preferred, and among these particularly preferred polynucleotides, those with at least 95% are especially preferred. Furthermore, those with at
least 97% are highly preferred among those with at least 95%, and among those those with at
least 98% and at least 99% are particularly highly preferred, with at least 99% being the more
preferred.

Preferred embodiments are polynucleotides that encode polypeptides that retain
substantially the same biological function or activity as the mature polypeptide encoded by a
DNA of Table 1 [SEQ ID NOS:1, 5, 6, 9].

The invention further relates to polynucleotides that hybridize to the herein above-
described sequences. In this regard, the invention especially relates to polynucleotides that
hybridize under stringent conditions to the herein above-described polynucleotides. As herein
used, the terms "stringent conditions" and "stringent hybridization conditions" mean
hybridization will occur only if there is at least 95% and preferably at least 97% identity between
the sequences. An example of stringent hybridization conditions is overnight incubation at
42°C in a solution comprising: 50% formamide, 5x SSC (150mM NaCl, 15mM trisodium
citrate), 50 mM sodium phosphate (pH7.6), 5x Denhardt’s solution, 10% dextran sulfate,
and 20 micrograms/ml denatured, sheared salmon sperm DNA, followed by washing the
hybridization support in 0.1x SSC at about 65°C. Hybridization and wash conditions are
well known and exemplified in Sambrook, et al., Molecular Cloning: A Laboratory Manual,

The invention also provides a polynucleotide consisting essentially of a
polynucleotide sequence obtainable by screening an appropriate library containing the
complete gene for a polynucleotide sequence set forth in SEQ ID NO:1 under stringent
hybridization conditions with a probe having the sequence of said polynucleotide sequence
set forth in SEQ ID NO:1 or a fragment thereof; and isolating said DNA sequence.
Fragments useful for obtaining such a polynucleotide include, for example, probes and
primers described elsewhere herein.

As discussed additionally herein regarding polynucleotide assays of the invention, for
instance, polynucleotides of the invention as discussed above, may be used as a hybridization
probe for RNA, cDNA and genomic DNA to isolate full-length cDNAs and genomic clones
encoding valS and to isolate cDNA and genomic clones of other genes that have a high sequence
similarity to the valS gene. Such probes generally will comprise at least 15 bases. Preferably,
such probes will have at least 30 bases and may have at least 50 bases. Particularly preferred
probes will have at least 30 bases and will have 50 bases or less.

For example, the coding region of the valS gene may be isolated by screening using the
DNA sequence provided in SEQ ID NO: 1 to synthesize an oligonucleotide probe. A labeled
oligonucleotide having a sequence complementary to that of a gene of the invention is then used to screen a library of cDNA, genomic DNA or mRNA to determine which members of the library the probe hybridizes to.

The polynucleotides and polypeptides of the invention may be employed, for example, as research reagents and materials for discovery of treatments of and diagnostics for disease, particularly human disease, as further discussed herein relating to polynucleotide assays.

Polynucleotides of the invention that are oligonucleotides derived from the sequences of SEQ ID NOS: 1 and/or 2 may be used in the processes herein as described, but preferably for PCR, to determine whether or not the polynucleotides identified herein in whole or in part are transcribed in bacteria in infected tissue. It is recognized that such sequences will also have utility in diagnosis of the stage of infection and type of infection the pathogen has attained.

The invention also provides polynucleotides that may encode a polypeptide that is the mature protein plus additional amino or carboxyl-terminal amino acids, or amino acids interior to the mature polypeptide (when the mature form has more than one polypeptide chain, for instance). Such sequences may play a role in processing of a protein from precursor to a mature form, may allow protein transport, may lengthen or shorten protein half-life or may facilitate manipulation of a protein for assay or production, among other things. As generally is the case in vivo, the additional amino acids may be processed away from the mature protein by cellular enzymes.

A precursor protein, having the mature form of the polypeptide fused to one or more prosequences may be an inactive form of the polypeptide. When prosequences are removed such inactive precursors generally are activated. Some or all of the prosequences may be removed before activation. Generally, such precursors are called proproteins.

In sum, a polynucleotide of the invention may encode a mature protein, a mature protein plus a leader sequence (which may be referred to as a preprotein), a precursor of a mature protein having one or more prosequences that are not the leader sequences of a preprotein, or a preproprotein, which is a precursor to a proprotein, having a leader sequence and one or more prosequences, which generally are removed during processing steps that produce active and mature forms of the polypeptide.

Vectors, host cells, expression

The invention also relates to vectors that comprise a polynucleotide or polynucleotides of the invention, host cells that are genetically engineered with vectors of the invention and the production of polypeptides of the invention by recombinant techniques. Cell-free translation
systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the invention.

For recombinant production, host cells can be genetically engineered to incorporate expression systems or portions thereof or polynucleotides of the invention. Introduction of a polynucleotide into the host cell can be effected by methods described in many standard laboratory manuals, such as Davis et al., *BASIC METHODS IN MOLECULAR BIOLOGY*, (1986) and Sambrook et al., *MOLECULAR CLONING: A LABORATORY MANUAL*, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989), such as, calcium phosphate transfection, DEAE-dextran mediated transfection, transfection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction and infection.

Representative examples of appropriate hosts include bacterial cells, such as streptococci, staphylococci, enterococci *E. coli*, streptomyces and *Bacillus subtilis* cells; fungal cells, such as yeast cells and *Aspergillus* cells; insect cells such as *Drosophila* S2 and *Spodoptera* Sf9 cells; animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, 293 and Bowes melanoma cells; and plant cells.

A great variety of expression systems can be used to produce the polypeptides of the invention. Such vectors include, among others, chromosomal, episomal and virus-derived vectors, e.g., vectors derived from bacterial plasmids, from bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, such as cosmids and phagemids. The expression system constructs may contain control regions that regulate as well as engender expression. Generally, any system or vector suitable to maintain, propagate or express polynucleotides and/or to express a polypeptide in a host may be used for expression in this regard. The appropriate DNA sequence may be inserted into the expression system by any of a variety of well-known and routine techniques, such as, for example, those set forth in Sambrook et al., *MOLECULAR CLONING, A LABORATORY MANUAL*, (supra).

For secretion of the translated protein into the lumen of the endoplasmic reticulum, into the periplasmic space or into the extracellular environment, appropriate secretion signals may be incorporated into the expressed polypeptide. These signals may be endogenous to the polypeptide or they may be heterologous signals.
Polypeptides of the invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography, and lectin chromatography. Most preferably, high performance liquid chromatography is employed for purification. Well known techniques for refolding protein may be employed to regenerate active conformation when the polypeptide is denatured during isolation and/or purification.

**Diagnostic Assays**

This invention is also related to the use of the valS polynucleotides of the invention for use as diagnostic reagents. Detection of valS in a eukaryote, particularly a mammal, and especially a human, will provide a diagnostic method for diagnosis of a disease. Eukaryotes (herein also "individual(s)"), particularly mammals, and especially humans, infected with an organism comprising the valS gene may be detected at the nucleic acid level by a variety of techniques.

Nucleic acids for diagnosis may be obtained from an infected individual's cells and tissues, such as bone, blood, muscle, cartilage, and skin. Genomic DNA may be used directly for detection or may be amplified enzymatically by using PCR or other amplification technique prior to analysis. RNA or cDNA may also be used in the same ways. Using amplification, characterization of the species and strain of prokaryote present in an individual, may be made by an analysis of the genotype of the prokaryote gene. Deletions and insertions can be detected by a change in size of the amplified product in comparison to the genotype of a reference sequence. Point mutations can be identified by hybridizing amplified DNA to labeled valS polynucleotide sequences. Perfectly matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences in melting temperatures. DNA sequence differences may also be detected by alterations in the electrophoretic mobility of the DNA fragments in gels, with or without denaturing agents, or by direct DNA sequencing. See, e.g., Myers et al., *Science, 230*: 1242 (1985). Sequence changes at specific locations also may be revealed by nuclease protection assays, such as RNase and S1 protection or a chemical cleavage method. See, e.g., Cotton et al., *Proc. Natl. Acad. Sci., USA, 85*: 4397-4401 (1985).

Cells carrying mutations or polymorphisms in the gene of the invention may also be detected at the DNA level by a variety of techniques, to allow for serotyping, for example. For example, RT-PCR can be used to detect mutations. It is particularly preferred to used RT-PCR
in conjunction with automated detection systems, such as, for example, GeneScan. RNA or
cDNA may also be used for the same purpose, PCR or RT-PCR. As an example, PCR primers
complementary to a nucleic acid encoding valS can be used to identify and analyze mutations.
Examples of representative primers are shown below in Table 2.

<table>
<thead>
<tr>
<th>SEQ ID NO</th>
<th>PRIMER SEQUENCE</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>5'-ATGTCTAAAGAACTTTCTATCTAAA-3'</td>
</tr>
<tr>
<td>4</td>
<td>5'-TTATTTACCAACTTCTTCATCTC-3'</td>
</tr>
</tbody>
</table>

Table 2
Primers for amplification of valS polynucleotides

The invention further provides these primers with 1, 2, 3 or 4 nucleotides removed from
the 5' and/or the 3' end. These primers may be used for, among other things, amplifying valS
dNA isolated from a sample derived from an individual. The primers may be used to amplify
the gene isolated from an infected individual such that the gene may then be subject to various
techniques for elucidation of the DNA sequence. In this way, mutations in the DNA sequence
may be detected and used to diagnose infection and to serotype and/or classify the infectious
agent.

The invention further provides a process for diagnosing, disease, preferably bacterial
infections, more preferably infections by *Streptococcus pneumoniae*, and most preferably otitis
media, conjunctivitis, pneumonia, bacteremia, meningitis, sinusitis, pleural empyema and
endocarditis, and most particularly meningitis, such as for example infection of cerebrospinal
fluid, comprising determining from a sample derived from an individual a increased level of
expression of polynucleotide having the sequence of Table 1 [SEQ ID NO: 1]. Increased or
decreased expression of valS polynucleotide can be measured using any on of the methods
well known in the art for the quantation of polynucleotides, such as, for example,
amplification, PCR, RT-PCR, RNase protection, Northern blotting and other hybridization
methods.

In addition, a diagnostic assay in accordance with the invention for detecting over-
extression of valS protein compared to normal control tissue samples may be used to detect the
presence of an infection, for example. Assay techniques that can be used to determine levels of a
valS protein, in a sample derived from a host are well-known to those of skill in the art. Such
assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays.

**Antibodies**

The polypeptides of the invention or variants thereof, or cells expressing them can be used as an immunogen to produce antibodies immunospecific for such polypeptides. "Antibodies" as used herein includes monoclonal and polyclonal antibodies, chimeric, single chain, simianized antibodies and humanized antibodies, as well as Fab fragments, including the products of an Fab immunoglobulin expression library.

Antibodies generated against the polypeptides of the invention can be obtained by administering the polypeptides or epitope-bearing fragments, analogues or cells to an animal, preferably a nonhuman, using routine protocols. For preparation of monoclonal antibodies, any technique known in the art that provides antibodies produced by continuous cell line cultures can be used. Examples include various techniques, such as those in Kohler, G. and Milstein, C., *Nature* 256: 495-497 (1975); Kozbor et al., *Immunology Today* 4: 72 (1983); Cole et al., pg. 77-96 in *MONOCLONAL ANTIBODIES AND CANCER THERAPY*, Alan R. Liss, Inc. (1985).

Techniques for the production of single chain antibodies (U.S. Patent No. 4,946,778) can be adapted to produce single chain antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms such as other mammals, may be used to express humanized antibodies.

Alternatively phage display technology may be utilized to select antibody genes with binding activities towards the polypeptide either from repertoires of PCR amplified v-genes of lymphocytes from humans screened for possessing anti-valS or from naive libraries (McCafferty, J. et al., (1990), *Nature* 348, 552-554; Marks, J. et al., (1992) *Biotechnology* 10, 779-783). The affinity of these antibodies can also be improved by chain shuffling (Clackson, T. et al., (1991) *Nature* 352, 624-628).

If two antigen binding domains are present each domain may be directed against a different epitope – termed 'bispecific' antibodies.

The above-described antibodies may be employed to isolate or to identify clones expressing the polypeptides to purify the polypeptides by affinity chromatography.

Thus, among others, antibodies against valS- polypeptide may be employed to treat infections, particularly bacterial infections and especially otitis media, conjunctivitis, pneumonia, bacteremia, meningitis, sinusitis, pleural empyema and endocarditis, and most particularly meningitis, such as for example infection of cerebrospinal fluid.
Polypeptide variants include antigenically, epitopically or immunologically equivalent variants that form a particular aspect of this invention. The term "antigenically equivalent derivative" as used herein encompasses a polypeptide or its equivalent which will be specifically recognized by certain antibodies which, when raised to the protein or polypeptide according to the invention, interfere with the immediate physical interaction between pathogen and mammalian host. The term "immunologically equivalent derivative" as used herein encompasses a peptide or its equivalent which when used in a suitable formulation to raise antibodies in a vertebrate, the antibodies act to interfere with the immediate physical interaction between pathogen and mammalian host.

The polypeptide, such as an antigenically or immunologically equivalent derivative or a fusion protein thereof is used as an antigen to immunize a mouse or other animal such as a rat or chicken. The fusion protein may provide stability to the polypeptide. The antigen may be associated, for example by conjugation, with an immunogenic carrier protein for example bovine serum albumin (BSA) or keyhole limpet haemocyanin (KLH). Alternatively a multiple antigenic peptide comprising multiple copies of the protein or polypeptide, or an antigenically or immunologically equivalent polypeptide thereof may be sufficiently antigenic to improve immunogenicity so as to obviate the use of a carrier.

Preferably, the antibody or variant thereof is modified to make it less immunogenic in the individual. For example, if the individual is human the antibody may most preferably be "humanized"; where the complimentarity determining region(s) of the hybridoma-derived antibody has been transplanted into a human monoclonal antibody, for example as described in Jones, P. et al. (1986), Nature 321, 522-525 or Tempest et al., (1991) Biotechnology 9, 266-273.

Antagonists and agonists - assays and molecules

Polypeptides of the invention may also be used to assess the binding of small molecule substrates and ligands in, for example, cells, cell-free preparations, chemical libraries, and natural product mixtures. These substrates and ligands may be natural substrates and ligands or may be structural or functional mimetics. See, e.g., Coligan et al., Current Protocols in Immunology 1(2): Chapter 5 (1991).

The invention also provides a method of screening compounds to identify those which enhance (agonist) or block (antagonist) the action of valS polypeptides or polynucleotides, particularly those compounds that are bacteriostatic and/or bacteriocidal. The method of screening may involve high-throughput techniques. For example, to screen for agonists or antagonists, a synthetic reaction mix, a cellular compartment, such as a membrane, cell envelope or cell wall, or a preparation of any thereof, comprising valS polypeptide and a labeled substrate or ligand of such polypeptide is incubated in the absence or the presence of a candidate molecule that may be a valS agonist or antagonist. The ability of the candidate molecule to agonize or antagonize the valS polypeptide is reflected in decreased binding of the labeled ligand or decreased production of product from such substrate. Molecules that bind gratuitously, i.e., without inducing the effects of valS polypeptide are most likely to be good antagonists. Molecules that bind well and increase the rate of product production from substrate are agonists. Detection of the rate or level of production of product from substrate may be enhanced by using a reporter system. Reporter systems that may be useful in this regard include but are not limited to colorimetric labeled substrate converted into product, a reporter gene that is responsive to changes in valS polynucleotide or polypeptide activity, and binding assays known in the art.

Another example of an assay for valS antagonists is a competitive assay that combines valS and a potential antagonist with valS-binding molecules, recombinant valS binding molecules, natural substrates or ligands, or substrate or ligand mimetics, under appropriate conditions for a competitive inhibition assay. valS can be labeled, such as by radioactivity or a colorimetric compound, such that the number of valS molecules bound to a binding molecule or converted to product can be determined accurately to assess the effectiveness of the potential antagonist.

Potential antagonists include small organic molecules, peptides, polypeptides and antibodies that bind to a polynucleotide or polypeptide of the invention and thereby inhibit or extinguish its activity. Potential antagonists also may be small organic molecules, a peptide, a polypeptide such as a closely related protein or antibody that binds the same sites on a binding
molecule, such as a binding molecule, without inducing valS-induced activities, thereby preventing the action of valS by excluding valS from binding.

Potential antagonists include a small molecule that binds to and occupies the binding site of the polypeptide thereby preventing binding to cellular binding molecules, such that normal biological activity is prevented. Examples of small molecules include but are not limited to small organic molecules, peptides or peptide-like molecules. Other potential antagonists include antisense molecules (see Okano, J. Neurochem. 56: 560 (1991); Oligodeoxynucleotides as antisense inhibitors of gene expression, CRC Press, Boca Raton, FL (1988), for a description of these molecules). Preferred potential antagonists include compounds related to and variants of valS.

Each of the DNA sequences provided herein may be used in the discovery and development of antibacterial compounds. The encoded protein, upon expression, can be used as a target for the screening of antibacterial drugs. Additionally, the DNA sequences encoding the amino terminal regions of the encoded protein or Shine-Delgarno or other translation facilitating sequences of the respective mRNA can be used to construct antisense sequences to control the expression of the coding sequence of interest.

The invention also provides the use of the polypeptide, polynucleotide or inhibitor of the invention to interfere with the initial physical interaction between a pathogen and mammalian host responsible for sequelae of infection. In particular the molecules of the invention may be used: in the prevention of adhesion of bacteria, in particular gram positive bacteria, to mammalian extracellular matrix proteins on in-dwelling devices or to extracellular matrix proteins in wounds; to block valS protein-mediated mammalian cell invasion by, for example, initiating phosphorylation of mammalian tyrosine kinases (Rosenshine et al., Infect. Immun. 60:2211 (1992); to block bacterial adhesion between mammalian extracellular matrix proteins and bacterial valS proteins that mediate tissue damage and; to block the normal progression of pathogenesis in infections initiated other than by the implantation of in-dwelling devices or by other surgical techniques.

The agonists and antagonists of the invention may be employed, for instance, to inhibit and treat otitis media, conjunctivitis, pneumonia, bacteremia, meningitis, sinusitis, pleural empyema and endocarditis, and most particularly meningitis, such as for example infection of cerebrospinal fluid.

Vaccines

Another aspect of the invention relates to a method for inducing an immunological response in an individual, particularly a mammal which comprises inoculating the
individual with valS, or a fragment or variant thereof, adequate to produce antibody and/or T cell immune response to protect said individual from infection, particularly bacterial infection and most particularly *Streptococcus pneumoniae* infection. Also provided are methods whereby such immunological response slows bacterial replication. Yet another aspect of the invention relates to a method of inducing immunological response in an individual which comprises delivering to such individual a nucleic acid vector to direct expression of valS, or a fragment or a variant thereof, for expressing valS, or a fragment or a variant thereof in vivo in order to induce an immunological response, such as, to produce antibody and/or T cell immune response, including, for example, cytokine-producing T cells or cytotoxic T cells, to protect said individual from disease, whether that disease is already established within the individual or not. One way of administering the gene is by accelerating it into the desired cells as a coating on particles or otherwise. Such nucleic acid vector may comprise DNA, RNA, a modified nucleic acid, or a DNA/RNA hybrid.

A further aspect of the invention relates to an immunological composition which, when introduced into an individual capable or having induced within it an immunological response, induces an immunological response in such individual to a valS or protein coded therefrom, wherein the composition comprises a recombinant valS or protein coded therefrom comprising DNA which codes for and expresses an antigen of said valS or protein coded therefrom. The immunological response may be used therapeutically or prophylactically and may take the form of antibody immunity or cellular immunity such as that arising from CTL or CD4+ T cells.

A valS polypeptide or a fragment thereof may be fused with co-protein which may not by itself produce antibodies, but is capable of stabilizing the first protein and producing a fused protein which will have immunogenic and protective properties. Thus fused recombinant protein, preferably further comprises an antigenic co-protein, such as lipoprotein D from *Hemophilus influenzae*, Glutathione-S-transferase (GST) or beta-galactosidase, relatively large co-proteins which solubilize the protein and facilitate production and purification thereof. Moreover, the co-protein may act as an adjuvant in the sense of providing a generalized stimulation of the immune system. The co-protein may be attached to either the amino or carboxy terminus of the first protein.

Provided by this invention are compositions, particularly vaccine compositions, and methods comprising the polypeptides or polynucleotides of the invention and
immunostimulatory DNA sequences, such as those described in Sato, Y. et al. Science 273: 352 (1996).

Also, provided by this invention are methods using the described polynucleotide or particular fragments thereof which have been shown to encode non-variable regions of bacterial cell surface proteins in DNA constructs used in such genetic immunization experiments in animal models of infection with Streptococcus pneumoniae will be particularly useful for identifying protein epitopes able to provoke a prophylactic or therapeutic immune response. It is believed that this approach will allow for the subsequent preparation of monoclonal antibodies of particular value from the requisite organ of the animal successfully resisting or clearing infection for the development of prophylactic agents or therapeutic treatments of bacterial infection, particularly Streptococcus pneumoniae infection, in mammals, particularly humans.

The polypeptide may be used as an antigen for vaccination of a host to produce specific antibodies which protect against invasion of bacteria, for example by blocking adherence of bacteria to damaged tissue. Examples of tissue damage include wounds in skin or connective tissue caused, e.g., by mechanical, chemical or thermal damage or by implantation of indwelling devices, or wounds in the mucous membranes, such as the mouth, mammary glands, urethra or vagina.

The invention also includes a vaccine formulation which comprises an immunogenic recombinant protein of the invention together with a suitable carrier. Since the protein may be broken down in the stomach, it is preferably administered parenterally, including, for example, administration that is subcutaneous, intramuscular, intravenous, or intradermal. Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the bodily fluid, preferably the blood, of the individual; and aqueous and non-aqueous sterile suspensions which may include suspending agents or thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to use. The vaccine formulation may also include adjuvant systems for enhancing the immunogenicity of the formulation, such as oil-in water systems and other systems known in the art. The dosage will depend on the specific activity of the vaccine and can be readily determined by routine experimentation.
While the invention has been described with reference to certain ValS protein, it is to be understood that this covers fragments of the naturally occurring protein and similar proteins with additions, deletions or substitutions which do not substantially affect the immunogenic properties of the recombinant protein.

**Compositions, kits and administration**

The invention also relates to compositions comprising the polynucleotide or the polypeptides discussed above or their agonists or antagonists. The polypeptides of the invention may be employed in combination with a non-sterile or sterile carrier or carriers for use with cells, tissues or organisms, such as a pharmaceutical carrier suitable for administration to a subject. Such compositions comprise, for instance, a media additive or a therapeutically effective amount of a polypeptide of the invention and a pharmaceutically acceptable carrier or excipient. Such carriers may include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol and combinations thereof. The formulation should suit the mode of administration. The invention further relates to diagnostic and pharmaceutical packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention.

Polypeptides and other compounds of the invention may be employed alone or in conjunction with other compounds, such as therapeutic compounds.

The pharmaceutical compositions may be administered in any effective, convenient manner including, for instance, administration by topical, oral, anal, vaginal, intravenous, intraperitoneal, intramuscular, subcutaneous, intranasal or intradermal routes among others.

In therapy or as a prophylactic, the active agent may be administered to an individual as an injectable composition, for example as a sterile aqueous dispersion, preferably isotonic.

Alternatively the composition may be formulated for topical application for example in the form of ointments, creams, lotions, eye ointments, eye drops, ear drops, mouthwash, impregnated dressings and sutures and aerosols, and may contain appropriate conventional additives, including, for example, preservatives, solvents to assist drug penetration, and emollients in ointments and creams. Such topical formulations may also contain compatible conventional carriers, for example cream or ointment bases, and ethanol or oleyl alcohol for lotions. Such carriers may constitute from about 1% to about 98% by weight of the formulation; more usually they will constitute up to about 80% by weight of the formulation.
For administration to mammals, and particularly humans, it is expected that the daily dosage level of the active agent will be from 0.01 mg/kg to 10 mg/kg, typically around 1 mg/kg. The physician in any event will determine the actual dosage which will be most suitable for an individual and will vary with the age, weight and response of the particular individual. The above dosages are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention.

In-dwelling devices include surgical implants, prosthetic devices and catheters, i.e., devices that are introduced to the body of an individual and remain in position for an extended time. Such devices include, for example, artificial joints, heart valves, pacemakers, vascular grafts, vascular catheters, cerebrospinal fluid shunts, urinary catheters, continuous ambulatory peritoneal dialysis (CAPD) catheters.

The composition of the invention may be administered by injection to achieve a systemic effect against relevant bacteria shortly before insertion of an in-dwelling device. Treatment may be continued after surgery during the in-body time of the device. In addition, the composition could also be used to broaden perioperative cover for any surgical technique to prevent bacterial wound infections, especially *Streptococcus pneumoniae* wound infections.

Many orthopaedic surgeons consider that humans with prosthetic joints should be considered for antibiotic prophylaxis before dental treatment that could produce a bacteremia. Late deep infection is a serious complication sometimes leading to loss of the prosthetic joint and is accompanied by significant morbidity and mortality. It may therefore be possible to extend the use of the active agent as a replacement for prophylactic antibiotics in this situation.

In addition to the therapy described above, the compositions of this invention may be used generally as a wound treatment agent to prevent adhesion of bacteria to matrix proteins exposed in wound tissue and for prophylactic use in dental treatment as an alternative to, or in conjunction with, antibiotic prophylaxis.

Alternatively, the composition of the invention may be used to bathe an indwelling device immediately before insertion. The active agent will preferably be present at a concentration of 1μg/ml to 10mg/ml for bathing of wounds or indwelling devices.

A vaccine composition is conveniently in injectable form. Conventional adjuvants may be employed to enhance the immune response. A suitable unit dose for vaccination is 0.5-5 microgram/kg of antigen, and such dose is preferably administered 1-3 times and
Example 2  \textit{valS} Characterization

The enzyme mediated incorporation of radiolabelled amino acid into tRNA may be measured by the aminoacylation method which measures amino acid-tRNA as trichloroacetic acid-precipitable radioactivity from radiolabelled amino acid in the presence of tRNA and ATP (Hughes J, Mellows G and Soughton S, 1980, FEBS Letters, 122:322-324). Thus inhibitors of valyl tRNA synthetase can be detected by a reduction in the trichloroacetic acid precipitable radioactivity relative to the control. Alternatively the tRNA synthetase catalysed partial PPi/ATP exchange reaction which measures the formation of radiolabelled ATP from PPi can be used to detect valyl tRNA synthetase inhibitors (Calender R & Berg P, 1966, Biochemistry, 5, 1681-1690).
with an interval of 1-3 weeks. With the indicated dose range, no adverse toxicological
effects will be observed with the compounds of the invention which would preclude their
administration to suitable individuals.

Each reference disclosed herein is incorporated by reference herein in its entirety.

Any patent application to which this application claims priority is also incorporated by
reference herein in its entirety.

EXAMPLES

The examples below are carried out using standard techniques, which are well known
and routine to those of skill in the art, except where otherwise described in detail. The examples
are illustrative, but do not limit the invention.

Example 1 Strain selection, Library Production and Sequencing

The polynucleotide having the DNA sequence given in SEQ ID NO:1 was obtained
from a library of clones of chromosomal DNA of *Streptococcus pneumoniae* in *E. coli*. The
sequencing data from two or more clones containing overlapping *Streptococcus pneumoniae*
DNAs was used to construct the contiguous DNA sequence in SEQ ID NO:1. Libraries
may be prepared by routine methods, for example:

Methods 1 and 2 below.

Total cellular DNA is isolated from *Streptococcus pneumoniae* 0100993 according to
standard procedures and size-fractionated by either of two methods.

Method 1

Total cellular DNA is mechanically sheared by passage through a needle in order to
size-fractionate according to standard procedures. DNA fragments of up to 11kb in size are
rendered blunt by treatment with exonuclease and DNA polymerase, and EcoRI linkers
added. Fragments are ligated into the vector Lambda ZapII that has been cut with EcoRI,
the library packaged by standard procedures and *E.coli* infected with the packaged library.
The library is amplified by standard procedures.

Method 2

Total cellular DNA is partially hydrolyzed with a one or a combination of
restriction enzymes appropriate to generate a series of fragments for cloning into library
vectors - (e.g., RsaI, PstI, AluI, BshI235I), and such fragments are size-fractionated
according to standard procedures. EcoRI linkers are ligated to the DNA and the fragments
then ligated into the vector Lambda ZapII that have been cut with EcoRI, the library
packaged by standard procedures, and *E.coli* infected with the packaged library. The library
is amplified by standard procedures.
SEQUENCE LISTING

(1) GENERAL INFORMATION

(i) APPLICANT: Lawlor, Elizabeth

(ii) TITLE OF THE INVENTION: Novel Compounds

(iii) NUMBER OF SEQUENCES: 10

(iv) CORRESPONDENCE ADDRESS:
    (A) ADDRESSEE: SmithKline Beecham Corporation
    (B) STREET: 709 Swedeland Road
    (C) CITY: King of Prussia
    (D) STATE: PA
    (E) COUNTRY: USA
    (F) ZIP: 19406-0939

(v) COMPUTER READABLE FORM:
    (A) MEDIUM TYPE: Diskette
    (B) COMPUTER: IBM Compatible
    (C) OPERATING SYSTEM: DOS
    (D) SOFTWARE: FastSEQ for Windows Version 2.0

(vi) CURRENT APPLICATION DATA:
    (A) APPLICATION NUMBER:
    (B) FILING DATE: 18-APR-1997
    (C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:
    (A) APPLICATION NUMBER: 9607991.8
    (B) FILING DATE: 18-APR-1996

(viii) ATTORNEY/AGENT INFORMATION:
    (A) NAME: Gimmi, Edward R
    (B) REGISTRATION NUMBER: 38,891
    (C) REFERENCE/DOCKET NUMBER: P31458-4

(ix) TELECOMMUNICATION INFORMATION:
    (A) TELEPHONE: 610-270-4478
    (B) TELEFAX: 610-270-5090
    (C) TELEX: 35
(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 540 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Genomic DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

ATGTCTAAAG AACTTTTCATC TAAATAACAAT CCAGCCGAGG TTGAGGCTGG TCGTTACCAA 60
AAATGGCTTG ATGCTGTATG TTTCAAGCCT TCGGGGATC AAAAGGCTAA GCGTTTATTC 120
ATCGTTATTTC CACCCACAAA CGTTACAGT AAACTCACC TTGGTCAGCC TTGGGATACA 180
ACTTGGCAAG ATATTATCAC CGGTCAAATA CGATAGCAAG GTTTGTATAC CCTTTGGCTT 240
CCTGGGATGG ACCACGCAGG GATTGCCACT CAGGCTAAAG TAGAGGAGCG CTTGCCGTTG 300
GAGGGCATTT CCCGCTATGA CCTTGGCTCGT GAGTCTTCTCT TAGCGAAAGT CTGGGAATGG 360
AAAGACCGAAT ATGCCACTAC TATCAAGGAA CAATGGGCGA AGATGGGCGT CTTCTGAGAC 420
TATTCCTCGTG ACGGTTCACG TCTTGAGCGA GGTGTTGCAA AAGCTGTTCG TAAGGTCTTT 480
GTGGACCTTT ACAAGAAAGG CTGGATCTAC CGTGGTGAGT TTATCATAAA CTGGGACCCA 540

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 180 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

<table>
<thead>
<tr>
<th></th>
<th>Met</th>
<th>Ser</th>
<th>Lys</th>
<th>Glu</th>
<th>Leu</th>
<th>Ser</th>
<th>Ser</th>
<th>Lys</th>
<th>Tyr</th>
<th>Asn</th>
<th>Pro</th>
<th>Ala</th>
<th>Glu</th>
<th>Val</th>
<th>Glu</th>
<th>Ala</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>5</td>
<td>10</td>
<td>15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gly</td>
<td></td>
<td>Arg</td>
<td>Tyr</td>
<td>Gln</td>
<td>Lys</td>
<td>Trp</td>
<td>Leu</td>
<td>Asp</td>
<td>Ala</td>
<td>Asp</td>
<td>Val</td>
<td>Phe</td>
<td>Lys</td>
<td>Pro</td>
<td>Ser</td>
<td>Gly</td>
</tr>
<tr>
<td></td>
<td>20</td>
<td></td>
<td></td>
<td>25</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asp</td>
<td></td>
<td>Gln</td>
<td>Lys</td>
<td>Ala</td>
<td>Lys</td>
<td>Pro</td>
<td>Tyr</td>
<td>Ser</td>
<td>Ile</td>
<td>Val</td>
<td>Ile</td>
<td>Pro</td>
<td>Pro</td>
<td>Pro</td>
<td>Asn</td>
<td>Val</td>
</tr>
<tr>
<td></td>
<td>35</td>
<td>40</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thr</td>
<td></td>
<td>Gly</td>
<td>Lys</td>
<td>Leu</td>
<td>His</td>
<td>Leu</td>
<td>Gly</td>
<td>His</td>
<td>Ala</td>
<td>Trp</td>
<td>Asp</td>
<td>Thr</td>
<td>Thr</td>
<td>Leu</td>
<td>Gln</td>
<td>Asp</td>
</tr>
<tr>
<td></td>
<td>50</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ile</td>
<td>Ile</td>
<td>Ile</td>
<td>Arg</td>
<td>Gln</td>
<td>Lys</td>
<td>Arg</td>
<td>Met</td>
<td>Gln</td>
<td>Gly</td>
<td>Phe</td>
<td>Asp</td>
<td>Thr</td>
<td>Leu</td>
<td>Trp</td>
<td>Leu</td>
<td></td>
</tr>
<tr>
<td></td>
<td>65</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

36
Pro Gly Met Asp His Ala Gly Ile Ala Thr Gln Ala Lys Val Glu Glu 85 90 95
Arg Leu Arg Gly Glu Gly Ile Ser Arg Tyr Asp Leu Gly Arg Glu Ser 100 105 110
Phe Leu Thr Lys Val Trp Glu Trp Lys Asp Glu Tyr Ala Thr Thr Thr Ile 115 120 125
Lys Glu Gln Trp Gly Lys Met Gly Leu Ser Val Asp Tyr Ser Arg Glu 130 135 140
Arg Phe Thr Leu Asp Gly Leu Ser Lys Ala Val Arg Lys Val Phe 145 150 155 160
Val Asp Leu Tyr Lys Lys Gly Trp Ile Tyr Arg Gly Glu Phe Ile Ile 165 170 175
Asn Trp Asp Pro 180

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Genomic DNA

(xii) SEQUENCE DESCRIPTION: SEQ ID NO:3:

ATGTCTAAAG AACTTTCATC TAAA

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Genomic DNA

(xii) SEQUENCE DESCRIPTION: SEQ ID NO:4:

TTATTTCACC AACTTCTTCA TCTC

(2) INFORMATION FOR SEQ ID NO:5:

37
(i) SEQUENCE CHARACTERISTICS:
   (A) LENGTH: 1269 base pairs
   (B) TYPE: nucleic acid
   (C) STRANDEDNESS: single
   (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Genomic DNA

(x) SEQUENCE DESCRIPTION: SEQ ID NO:5:

ATGCTGGAAG ATGGTCAAG CAGTCTTGAAG GGGGCTTAA CACTGTCTGA AATCAGTCTTCA
GGCCGCAGCT CGGCTGGGTC ATGTGACATG GACCAATTTC TAAGATATC
ATGCTGTAAG CTGGATGGA AAGAATGTTTT GAGCTGGTGAG CTGGCTGAG
TTGCTGGGTC ATGTGGTCTG TGCTGGTCAG GTGCGAAGCT GGCTGATGC
GGCCAGCTA CTGGCGTCTA CTGCTGCTGA GCCTGCTGCTG GACTGCTGCTG
GCTGCTGCTG GCTGCTGCTG GCTGCTGCTG GCTGCTGCTG GCTGCTGCTG
GAATATGGCC CAGGCGCTAA AGCTGCTGCTG GCTGCTGCTG GCTGCTGCTG

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:
   (A) LENGTH: 333 base pairs
   (B) TYPE: nucleic acid
   (C) STRANDEDNESS: single
   (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Genomic DNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

ATCAAAACGT TTACAAATCC AGAAACCTTG GAAATCGCAT CAACCATCCC TGCCACTGGA
CTGGCTATGT CAACGGTTAT TACAGAGGCC GAAATCTTCT TGCCACTGGT AGACCTCTTG
AATGTGAAG AAGAATTGGC AGGTCTGAAA AAAGAATTTG CCAAATGGCA GAAAGAACTC
GACATGGTGT GCCAAAAACT CAGCAAAGAA CGCTTCTGCG CCAACGCTAA ACCAGAAGTT
GTCCAAAAAG AAAAGACAAA ACAAGCGGAC TACCAAGGCA AGTATGATGT GACCGTAGCA
CGTATTGATG AGATGAAGAA GTTGCTGAAA TAA

(2) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 423 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

<table>
<thead>
<tr>
<th></th>
<th>Met</th>
<th>Leu</th>
<th>Glu</th>
<th>Asp</th>
<th>Gly</th>
<th>Ser</th>
<th>Arg</th>
<th>Val</th>
<th>Leu</th>
<th>Glu</th>
<th>Val</th>
<th>Ala</th>
<th>Thr</th>
<th>Thr</th>
<th>Thr</th>
<th>Arg</th>
<th>Pro</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

|   | Glu | Thr | Met | Phe | Gly | Asp | Val | Ala | Val | Ala | Val | Asn | Pro | Glu | Asp | Pro |   |
|---|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|---|
| 20|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |   |
| 25|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |   |
| 30|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |   |

|   | Arg | Tyr | Lys | Asp | Leu | Ile | Gly | Lys | Asn | Val | Ile | Leu | Pro | Ile | Ala | Asn |   |
|---|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|---|
| 35|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |   |
| 40|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |   |
| 45|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |   |

|   | Lys | Leu | Ile | Val | Gly | Asp | Glu | His | Ala | Asp | Pro | Glu | Phe | Gly |   |   |
|---|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|---|---|
| 50|     |     |     |     |     |     |     |     |     |     |     |     |     |   |   |
| 55|     |     |     |     |     |     |     |     |     |     |     |     |     |   |   |
| 60|     |     |     |     |     |     |     |     |     |     |     |     |     |   |   |

|   | Thr | Gly | Val | Val | Lys | Ile | Thr | Pro | Ala | His | Asp | Asp | Asp | Phe | Leu |   |
|---|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|---|
| 65|     |     |     |     |     |     |     |     |     |     |     |     |     |     |   |
| 70|     |     |     |     |     |     |     |     |     |     |     |     |     |     |   |
| 75|     |     |     |     |     |     |     |     |     |     |     |     |     |     |   |
| 80|     |     |     |     |     |     |     |     |     |     |     |     |     |     |   |

|   | Val | Gly | Gln | Arg | His | Leu | Pro | Gln | Val | Asn | Val | Met | Asn | Asp | Asp |   |
|---|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|---|
| 85|     |     |     |     |     |     |     |     |     |     |     |     |     |     |   |
| 90|     |     |     |     |     |     |     |     |     |     |     |     |     |     |   |
| 95|     |     |     |     |     |     |     |     |     |     |     |     |     |     |   |

|   | Gly | Thr | Met | Asn | Asp | Leu | Ala | Phe | Glu | Phe | Ser | Gly | Met | Asp | Arg | Phe |   |
|---|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|---|
|100|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |   |
|105|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |   |
|110|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |   |

|   | Glu | Ala | Arg | Lys | Ala | Val | Val | Ala | Lys | Leu | Glu | Glu | Ile | Gly | Ala | Leu |   |
|---|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|---|
|115|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |   |
|120|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |   |
|125|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |   |

|   | Val | Lys | Ile | Glu | Lys | Arg | Val | His | Ser | Val | Gly | His | Ser | Gly | Arg | Thr |   |
|---|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|---|
|130|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |   |
|135|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |   |
|140|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |   |

|   | Gly | Val | Val | Glu | Pro | Arg | Leu | Ser | Thr | Gln | Trp | Phe | Val | Lys | Met |   |
|---|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|---|
|145|     |     |     |     |     |     |     |     |     |     |     |     |     |     |   |
|150|     |     |     |     |     |     |     |     |     |     |     |     |     |     |   |
|155|     |     |     |     |     |     |     |     |     |     |     |     |     |     |   |
|160|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |   |

|   | Asp | Gln | Leu | Ala | Lys | Asn | Ala | Ile | Ala | Asn | Gln | Asp | Thr | Glu | Asp | Lys |   |
|---|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|---|
|165|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |   |
|170|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |   |
|175|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |   |
Val Glu Phe Tyr Pro Pro Arg Phe Asn Asp Thr Phe Leu Gln Trp Met 180 185 190
Glu Asn Val His Asp Trp Val Ile Ser Arg Gln Leu Trp Trp Gly His 195 200 205
Gln Ile Pro Ala Trp Tyr Asn Ala Asp Gly Glu Met Tyr Val Gly Glu 210 215 220
Glu Ala Pro Glu Gly Asp Gly Trp Thr Gln Asp Glu Asp Val Leu Asp 225 230 235 240
Thr Trp Phe Ser Ser Ala Leu Trp Pro Phe Ser Thr Met Gly Trp Pro 245 250 255
Glu Val Asp Ser Glu Asp Phe Lys Arg Tyr Phe Pro Thr Ser Thr Leu 260 265 270
Val Thr Gly Tyr Asp Ile Ile Phe Phe Trp Val Ser Arg Met Ile Phe 275 280 285
Gln Ser Leu Glu Phe Thr Gly Arg Gln Pro Phe Gln Asn Val Leu Ile 290 295 300
His Gly Leu Ile Arg Asp Glu Gln Gly Arg Lys Met Ser Lys Ser Leu 305 310 315 320
Gly Asn Gly Ile Asp Pro Met Asp Val Ile Glu Lys Tyr Gly Ala Asp 325 330 335
Ala Leu Arg Trp Phe Leu Ser Asn Gly Ser Ala Pro Gly Gln Asp Val 340 345 350
Arg Phe Ser Tyr Glu Lys Met Asp Ala Ser Trp Asn Phe Ile Asn Lys 355 360 365
Ile Trp Asn Ile Ser Arg Tyr Ile Leu Met Asn Gly Gly Leu Thr 370 375 380
Leu Asp Val Ala His Asp Val Thr Lys Val Ala Thr Gly Glu Ala 385 390 395 400
Gly Asn Val Thr Asp Arg Trp Ile Leu His Asn Leu Asn Glu Thr Ile 405 410 415
Ala Lys Val Thr Glu Asn Phe 420

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 110 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:
Ile Lys Arg Phe Thr Asn Pro Glu His Leu Glu Ile Ala Ser Thr Thr Ile
 1    5      10     15
Pro Ala Pro Glu Ala Met Ser Ser Val Ile Thr Gly Ala Glu Ile
20    25     30
Phe Leu Pro Leu Val Asp Leu Asn Val Glu Glu Leu Ala Arg
35    40     45
Leu Glu Lys Glu Leu Ala Lys Trp Gln Lys Glu Leu Asp Met Val Gly
50    55     60
Lys Lys Leu Ser Asn Glu Arg Phe Val Ala Asn Ala Lys Pro Glu Val
65    70     80
Val Gln Lys Glu Lys Glu Asp Lys Gln Ala Asp Tyr Gln Ala Lys Tyr Asp
85    90     95
Val Thr Val Ala Arg Ile Asp Glu Met Lys Leu Val Lys
100   105    110

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 469 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Genomic DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

CTGATGTTTC AAGCTTCAGG CGATCAAAG GCTAAGCCTT ATTCAATGCT TATTCCACCA 60
CCAAAGGTTA CAGGATAACT TCACCTTGGT CACGCTTGGA ATACAACCTT GCCAGATATT 120
ATCATCCGTC AAAAACACAT CCAAGGTTTTT GATACCCCTT GGCTTCTGGG GATGGACCAC 180
GCAGGGATTC CCACCTAGGC TAAGGCTAGG GAGCGCTTGC GTCGGTGAAG GACTTCCGCC 240
TTAGACTATC GTGCTGAGTC TTTCTGAGCG AAGGCTGCGG AATGGGAAGA CGAATATGCC 300
ACTACTATCA AGGAAACAATG GGGCAAGATG GGGCTCTCTG TAGACTATTC TCGTGAGCGT 360
TTCACTCTGG ACGAAGGTTT GTCAAAAAGCT GTTCGTAAGG TCTTTTGAGCA CTTTTACAAG 420
AAAGGCTCGGA TCTACCGTGG TGAGTCTATC ATCAACTGCG ACCACGCAG 469

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 156 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

41
(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Leu Met Phe Gln Ala Ser Gly Asp Gln Lys Ala Lys Pro Tyr Ser Met 1  5  10  15
Val Ile Pro Pro Pro Asn Val Thr Gly Lys Leu His Leu Gly His Ala 20 25 30
Trp Asp Thr Thr Leu Gln Asp Ile Ile Ile Arg Gln Lys Arg Met Gln 35 40 45
Gly Phe Asp Thr Leu Trp Leu Pro Gly Met Asp His Ala Gly Ile Ala 50 55 60
Thr Gln Ala Lys Val Glu Glu Arg Leu Arg Gly Glu Gly Ile Ser Arg 65 70 75 80
Tyr Asp Leu Gly Arg Glu Ser Phe Leu Thr Lys Val Trp Glu Trp Lys 85 90 95
Asp Glu Tyr Ala Thr Thr Ile Lys Glu Gln Trp Gly Lys Met Gly Leu 100 105 110
Ser Val Asp Tyr Ser Arg Glu Arg Phe Thr Leu Asp Glu Gly Leu Ser 115 120 125
Lys Ala Val Arg Lys Val Phe Val Asp Leu Tyr Lys Lys Gly Trp Ile 130 135 140
Tyr Arg Gly Glu Phe Ile Ile Asn Trp Asp Pro Ala 145 150 155
What is claimed is:

1. An isolated polynucleotide comprising a polynucleotide sequence selected from
the group consisting of:
   (a) a polynucleotide having at least a 70% identity to a polynucleotide encoding a
polypeptide comprising the amino acid sequence of SEQ ID NO:2, 7, 8 or 10;
   (b) a polynucleotide which is complementary to the polynucleotide of (a);
   (c) a polynucleotide having at least a 70% identity to a polynucleotide encoding the
same mature polypeptide expressed by the valS gene contained in the Streptococcus pneumoniae
of the deposited strain; and
   (d) a polynucleotide comprising at least 15 sequential bases of the polynucleotide
of (a), (b) or (c).

2. The polynucleotide of Claim 1 wherein the polynucleotide is DNA.
3. The polynucleotide of Claim 1 wherein the polynucleotide is RNA.
4. The polynucleotide of Claim 2 comprising the nucleic acid sequence set forth in
SEQ ID NO:1, 5, 6 or 9.
5. The polynucleotide of Claim 2 comprising nucleotide 1 (Fragment 1) to 330
(Fragment 3) set forth in SEQ ID NO:1, 5, 6 or 9.
6. The polynucleotide of Claim 2 which encodes a polypeptide comprising the
amino acid sequence of SEQ ID NO:2, 7, 8 or 10.

7. A vector comprising the polynucleotide of Claim 1.
8. A host cell comprising the vector of Claim 7.
9. A process for producing a polypeptide comprising: expressing from the host
cell of Claim 8 a polypeptide encoded by said DNA.
10. A process for producing a valS polypeptide or fragment comprising
culturing a host of claim 8 under conditions sufficient for the production of said polypeptide
or fragment.
11. A polypeptide comprising an amino acid sequence which is at least 70%
identical to the amino acid sequence of SEQ ID NO:2, 7, 8 or 10.
12. A polypeptide comprising an amino acid sequence as set forth in SEQ ID NO:2,
7, 8 or 10.
13. An antibody against the polypeptide of claim 11.
14. An antagonist which inhibits the activity or expression of the polypeptide of
claim 11.
15. A method for the treatment of an individual in need of valS polypeptide comprising: administering to the individual a therapeutically effective amount of the polypeptide of claim 11.

16. A method for the treatment of an individual having need to inhibit valS polypeptide comprising: administering to the individual a therapeutically effective amount of the antagonist of Claim 14.

17. A process for diagnosing a disease related to expression or activity of the polypeptide of claim 11 in an individual comprising:
   (a) determining a nucleic acid sequence encoding said polypeptide, and/or
   (b) analyzing for the presence or amount of said polypeptide in a sample derived from the individual.

18. A method for identifying compounds which interact with and inhibit or activate an activity of the polypeptide of claim 11 comprising:
   contacting a composition comprising the polypeptide with the compound to be screened under conditions to permit interaction between the compound and the polypeptide to assess the interaction of a compound, such interaction being associated with a second component capable of providing a detectable signal in response to the interaction of the polypeptide with the compound;
   and determining whether the compound interacts with and activates or inhibits an activity of the polypeptide by detecting the presence or absence of a signal generated from the interaction of the compound with the polypeptide.

19. A method for inducing immunological response in a mammal which comprises inoculating the mammal with valS polypeptide of claim 11, or a fragment or variant thereof, adequate to produce antibody and/or T cell immune response to protect said animal from disease.

20. A method of inducing immunological response in a mammal which comprises delivering a nucleic acid vector to direct expression of valS polypeptide of claim 11, or fragment or a variant thereof, for expressing said valS polypeptide, or a fragment or a variant thereof in vivo in order to induce an immunological response to produce antibody and/or T cell immune response to protect said animal from disease.
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER
IPC(6) : Please See Extra Sheet.
US CL : Please See Extra Sheet.
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
Minimum documentation searched (classification system followed by classification symbols)
U.S. : 420/190.1; 435/6, 69.1, 252.3, 320.1; 530/350, 387.1, 388.4; 536/23.7

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
APS, MEDLINE, EMBASE, BIOSIS
search terms: Streptococcus, valS, valyl tRNA synthetase

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category*</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>US 5,476,929 A (BRILES et al) 19 December 1995, see entire document.</td>
<td>1-6</td>
</tr>
</tbody>
</table>

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed
- "P+" document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search
23 JUNE 1997

Date of mailing of the international search report
06 AUG 1997

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231
Facsimile No. (703) 305-3230

Authorized officers
ANTHONY C. CAPUTA

Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)*
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER:
IPCl(6):

A61K 39/09; C12N 5/10, 9/00, 15/31; C12Q 1/14; C07 K 14/315, 16/12

A. CLASSIFICATION OF SUBJECT MATTER:
US Cl:

420/190.1; 435/6, 69.1, 252.3, 320.1; 530/350, 387.1, 388.4; 536/23.7